Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -0.13% WACC % is 4.13% as of Jul. 14, 2026. The stock has 4 warning signs investors should review. Among 1,022 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks better than 83.66% on this metric.
As of today (2026-07-14), CTT Pharmaceutical Holdings's weighted average cost of capital is 4.13%%. CTT Pharmaceutical Holdings's ROIC % is -171.11% (calculated using TTM income statement data).
CTT Pharmaceutical Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.
For a comprehensive WACC calculation, please access the WACC Calculator.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, CTT Pharmaceutical Holdings's weighted average cost of capital is 4.13%%. CTT Pharmaceutical Holdings's ROIC % is -171.11% (calculated using TTM income statement data).
CTT Pharmaceutical Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
Related Terms
CTT Pharmaceutical Holdings WACC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings WACC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's WACC % distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, CTT Pharmaceutical Holdings's market capitalization (E) is $4.687 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, CTT Pharmaceutical Holdings's latest one-year annual average Book Value of Debt (D) is $0.018 Mil.
a) weight of equity = E / (E + D) = 4.687 / (4.687 + 0.018) = 0.9962
b) weight of debt = D / (E + D) = 0.018 / (4.687 + 0.018) = 0.0038
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.589%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. CTT Pharmaceutical Holdings's beta is -0.0813.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.589% + -0.0813 * 6% = 4.1012%
3. Cost of Debt:
GuruFocus uses latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
As of Dec. 2025, CTT Pharmaceutical Holdings's interest expense (positive number) was $0.002 Mil. Its total Book Value of Debt (D) is $0.018 Mil.
Cost of Debt = 0.002 / 0.018 = 11.1111%.
4. Multiply by one minus annual Tax Rate:
GuruFocus uses the most recent annual Tax Expense divided by the most recent annual Pre-Tax Income to calculate the tax rate. The calculated annual tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated annual Tax Rate = 0 / -0.156 = 0%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings (CTTH) has a WACC % of 4.13% as of Jul. 14, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #167 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 16.3%.
Is CTT Pharmaceutical Holdings' WACC % too high?
CTT Pharmaceutical Holdings' current WACC % is 4.13%. The Drug Manufacturers industry median WACC % is 9.01. CTT Pharmaceutical Holdings' value of 4.13% is 54.1% below this industry median. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #167 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CTT Pharmaceutical Holdings' WACC % compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #167 out of 1022 companies for WACC %. This places CTT Pharmaceutical Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median WACC % is 9.01. CTT Pharmaceutical Holdings' value of 4.13% is 54.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 9.01, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CTT Pharmaceutical Holdings's current WACC % of 4.13% is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median WACC % is 9.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current WACC % is 4.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current WACC % of 4.13%. The current WACC % is 4.13% and 54.1% below the Drug Manufacturers industry median of 9.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current WACC % is 4.13% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
